Literature DB >> 19729669

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.

Patrick A Flume1, Peter J Mogayzel, Karen A Robinson, Christopher H Goss, Randall L Rosenblatt, Robert J Kuhn, Bruce C Marshall.   

Abstract

The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations These exacerbations typically warrant medical intervention. It is important that appropriate therapies are recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to define the key questions related to pulmonary exacerbations, review the clinical evidence using an evidence-based methodology, and provide recommendations to clinicians. It is hoped that these guidelines will be helpful to clinicians in the treatment of individuals with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729669     DOI: 10.1164/rccm.200812-1845PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  190 in total

1.  Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.

Authors:  J Michael Collaco; Deanna M Green; Garry R Cutting; Kathleen M Naughton; Peter J Mogayzel
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

Review 2.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

Review 3.  The Lung Microbiome and Its Role in Pneumonia.

Authors:  Benjamin G Wu; Leopoldo N Segal
Journal:  Clin Chest Med       Date:  2018-12       Impact factor: 2.878

4.  Vancomycin Versus Vancomycin Plus Rifampin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis.

Authors:  Nicholas M Fusco; Calvin J Meaney; Corey Wells; Carla A Frederick; William A Prescott
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

5.  Safety of Extended Interval Tobramycin in Cystic Fibrosis Patients Less an 6 Years Old.

Authors:  Alexandria Arends; Rebecca Pettit
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

6.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

7.  New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.

Authors:  Janus A J Haagensen; Davide Verotta; Liusheng Huang; Alfred Spormann; Katherine Yang
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

Review 8.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

9.  Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.

Authors:  Lisa T Hong; Theodore G Liou; Rishi Deka; Jordan B King; Vanessa Stevens; David C Young
Journal:  Chest       Date:  2018-06-13       Impact factor: 9.410

10.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.